Andrew Peranteau, MD
Dermatology · New York, NYNPI 1588075386
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (49.0%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. AbbVie accounts for 68.6% of it on its own, with 27 other manufacturers making up the rest. 2025 is the largest year on record at $18,561, more than ten times the $231 reported in 2019.
Across 500 payments — averaging $61.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$21K
- Johnson & Johnson$982
- Regeneron Healthcare Solutions, Inc.$878
- Pfizer$832
- UCB, Inc.$819
- Lilly USA, LLC$758
- plus $5K from 22 others
Across 283 payments — averaging $2528.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Incyte Corporation$252K
- Kiniksa Pharmaceuticals, Ltd.$226K
- Pfizer$94K
- Sun Pharmaceutical Industries Inc.$44K
- Avita Medical Americas, LLC$27K
- Dr.reddy's Laboratories,inc.$24K
- plus $48K from 5 others
What the payments were for
- Consulting fees$2,2757%
- Speaking & faculty fees$14,95049%
- Travel & lodging$5992%
- Food & beverage$12,51041%
- Education$2051%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 125 | $20,937 |
| Johnson & Johnson | 40 | $982 |
| Regeneron Healthcare Solutions, Inc. | 23 | $878 |
| Pfizer | 39 | $832 |
| UCB, Inc. | 26 | $819 |
| Lilly USA, LLC | 39 | $758 |
| Novartis | 28 | $660 |
| Sun Pharmaceutical Industries Inc. | 23 | $589 |
| LEO Pharma Inc. | 26 | $574 |
| Journey Medical Corporation | 10 | $517 |
| Incyte Corporation | 16 | $455 |
| E.r. Squibb & Sons, L.L.C. | 21 | $413 |
| Dermavant Sciences, Inc. | 9 | $357 |
| Sanofi | 16 | $343 |
| Arcutis Biotherapeutics, Inc. | 18 | $302 |
| Amgen | 7 | $271 |
| Almirall LLC | 5 | $183 |
| Galderma Laboratories, L.p. | 8 | $157 |
| Janssen Scientific Affairs, LLC | 1 | $125 |
| VYNE Pharmaceuticals Inc. | 3 | $65 |
| Mayne Pharma Commercial LLC | 5 | $64 |
| Botanix SB Inc | 3 | $57 |
| Genentech USA, Inc. | 2 | $46 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 2 | $45 |
| Verrica Pharmaceuticals Inc. | 2 | $41 |
| Boehringer Ingelheim | 1 | $31 |
| Strata Skin Sciences, Inc. | 1 | $20 |
| LNHC, Inc | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$30,539 in reported general payments places this provider in the 85th percentile of 1,151 dermatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpzeluraRuxolitinib Phosphate | 14 | $27,486 |
| Acitretin | 11 | $3,190 |
| Tretinoin | 34 | $2,579 |
| Clobetasol Propionate | 40 | $1,849 |
| Metronidazole | 19 | $1,648 |
| Halobetasol Propionate | 25 | $1,643 |
| Clindamycin Phosphate | 29 | $1,177 |
| Ketoconazole | 95 | $1,134 |
| Ammonium Lactate | 40 | $806 |
| CiclopiroxCiclopirox Olamine | 11 | $764 |
| Fluocinonide | 22 | $680 |
| Triamcinolone Acetonide | 69 | $502 |
| Azelaic Acid | 11 | $391 |
| Hydrocortisone | 16 | $250 |
| Spironolactone | 14 | $237 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationOpzelura | $455 | $27,48614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,151 dermatology providers in New York.
Other dermatology in New York
- Alexandra GolantNew York$3.6M
- David CohenNew York$3M
- Michael CameronNew York$2.6M
- Saakshi KhattriNew York$2.4M
- Amy WechslerNew York$2.4M
- Joshua ZeichnerNew York$2.1M
- Emma GuttmanNew York$1.7M
- George HanNew York$1.6M
- Amy SpizuocoNew York$1.3M
- Andrew AlexisNew York$834K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.